{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T01:32:21Z","timestamp":1772155941739,"version":"3.50.1"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:p>\n                    Extramedullary leukemia (EML) is common in pediatric acute leukemia and can present at diagnosis or relapse. CD33 is detected on the surface of myeloid blasts in many patients with acute myelogenous leukemia and is the target of the antibody drug conjugate gemtuzumab ozogamicin (GO). Here we present 2 patients with CD33\n                    <jats:sup>+<\/jats:sup>\n                    EML treated with GO. They achieved significant response, with reduction of EML on both clinical and radiographic exams, specifically\n                    <jats:sup>18<\/jats:sup>\n                    fluorine fluorodeoxyglucose positron emission tomography\/computed tomography, demonstrating potential for targeted therapy with GO as a means of treating EML in patients with CD33\n                    <jats:sup>+<\/jats:sup>\n                    leukemia and the utility of\n                    <jats:sup>18<\/jats:sup>\n                    fluorine fluorodeoxyglucose positron emission tomography\/computed tomography monitoring in EML.\n                  <\/jats:p>","DOI":"10.1097\/mph.0000000000001201","type":"journal-article","created":{"date-parts":[[2018,5,6]],"date-time":"2018-05-06T20:00:53Z","timestamp":1525636853000},"page":"e174-e176","source":"Crossref","is-referenced-by-count":8,"title":["Clinical and Radiographic Response of Extramedullary Leukemia in Patients Treated With Gemtuzumab Ozogamicin"],"prefix":"10.1097","volume":"41","author":[{"given":"Michael J.","family":"McNeil","sequence":"first","affiliation":[{"name":"Pediatrics"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marguerite T.","family":"Parisi","sequence":"additional","affiliation":[{"name":"Pediatrics"},{"name":"Radiology, University of Washington School of Medicine, Seattle Children\u2019s Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuko","family":"Hijiya","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Northwestern University Feinberg School of Medicine"},{"name":"Division of Pediatric Hematology Oncology, Ann & Robert H Lurie Children\u2019s Hospital of Chicago, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soheil","family":"Meshinchi","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd","family":"Cooper","sequence":"additional","affiliation":[{"name":"Pediatrics"},{"name":"Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Tarlock","sequence":"additional","affiliation":[{"name":"Pediatrics"},{"name":"Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230918","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pbc.23201","article-title":"Superior outcome of pediatric acute myeloid leukemia patients with orbital and CNS myeloid sarcoma: a report from the Children\u2019s Oncology Group","volume":"58","author":"Johnston","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"R2-20230918","doi-asserted-by":"crossref","first-page":"e26520","DOI":"10.1002\/pbc.26520","article-title":"Extramedullary leukemia in children with acute myeloid leukemia: a population-based cohort study from the Nordic Society of Pediatric Hematology and Oncology NOPHO","volume":"64","author":"Stove","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"R3-20230918","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/sj.leu.2401971","article-title":"Extramedullary infiltrates at diagnosis have no prognostic significance in children with acute myeloid leukemia","volume":"10","author":"Bisschop","year":"2001","journal-title":"Leukemia"},{"key":"R4-20230918","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1080\/10428190600967196","article-title":"Granulocytic sarcoma: 32 cases and review of the literature","volume":"47","author":"Paydas","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"R5-20230918","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0733-8635(18)30190-6","article-title":"Leukemia cutis","volume":"12","author":"Ratnam","year":"1994","journal-title":"Dermatol Clin"},{"key":"R6-20230918","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1016\/j.ijrobp.2011.02.057","article-title":"Radiation therapy for chloroma (granulocytic sarcoma)","volume":"82","author":"Bakst","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R7-20230918","first-page":"1490","article-title":"Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia","volume":"7","author":"Bross","year":"2001","journal-title":"Clin Cancer Res"},{"key":"R8-20230918","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/cncr.21326","article-title":"Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence","volume":"104","author":"Larson","year":"2005","journal-title":"Cancer"},{"key":"R9-20230918","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2214\/AJR.06.1500","article-title":"Radiologic spectrum of extramedullary relapse of myelogenous leukemia in adults","volume":"189","author":"Fritz","year":"2007","journal-title":"AJR Am J Roentgenol"},{"key":"R10-20230918","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.2214\/AJR.11.7743","article-title":"Utility of FDG PET\/CT in the assessment of myeloid sarcoma","volume":"198","author":"Lee","year":"2012","journal-title":"AJR Am J Roentgenol"},{"key":"R11-20230918","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.3324\/haematol.2011.045047","article-title":"F-FDG-PET\/CT for detection of extramedullary acute myeloid leukemia","volume":"96","author":"Stolzel","year":"2011","journal-title":"Haematologica"},{"key":"R12-20230918","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/ejh.12085","article-title":"Extramedullary disease in patients with acute myeloid leukemia assessed by 18F-FDG PET","volume":"90","author":"Cribe","year":"2013","journal-title":"Eur J Haematol"},{"key":"R13-20230918","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/RLU.0000000000000999","article-title":"Use of 18F-FDG PET-CT for detection of active disease in acute myeloid leukemia","volume":"41","author":"Elojeimy","year":"2016","journal-title":"Clin Nucl Med"},{"key":"R14-20230918","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1200\/JCO.2015.62.6846","article-title":"CD33 expression and its association with gemtuzumab ozagamicin response: results from the Randomized Phase III Children\u2019s Oncology Group Trial AAML0531","volume":"34","author":"Pollard","year":"2016","journal-title":"J Clin Oncol"},{"key":"R15-20230918","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1182\/blood-2016-01-689976","article-title":"The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia","volume":"127","author":"Olombel","year":"2016","journal-title":"Blood"},{"key":"R16-20230918","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1158\/1078-0432.CCR-15-1349","article-title":"Gemtuzumab ozogamicin reduces relapse risk in FLT3\/ITD acute myeloid leukemia: a report from the Children\u2019s Oncology Group","volume":"22","author":"Tarlock","year":"2016","journal-title":"Clin Cancer Res"},{"key":"R17-20230918","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1002\/cncr.22524","article-title":"Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia","volume":"109","author":"Aribi","year":"2007","journal-title":"Cancer"},{"key":"R18-20230918","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.leukres.2004.01.004","article-title":"Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies","volume":"28","author":"Tsimberidou","year":"2004","journal-title":"Leuk Res"},{"key":"R19-20230918","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/ncponc0899","article-title":"Gemtuzumab therapy for isolated extramedullary AML relapse following allogeneic stem-cell transplant","volume":"4","author":"Owonikoko","year":"2007","journal-title":"Nat Clin Pract Oncol"},{"key":"R20-20230918","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.clml.2012.01.012","article-title":"Clinical binding properties, internalization kinetics, and clinicopathologic activity of brentuximab vedotin: an antibody conjugate for CD30-positive lymphoid neoplasms","volume":"12","author":"Fromm","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00043426-201904000-00030","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T01:22:29Z","timestamp":1695000149000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00043426-201904000-00030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000001201","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.733183872.793581849","asserted-by":"object"}]},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]}}}